Amedica Corporation (NASDAQ:AMDA)

Amedica Corporation (NASDAQ:AMDA), declared financial results for the third quarter ended September 30, 2015.

Recent Company Highlights

• Cash and cash equivalents totaled $11.3 million, and net cash used in operating activities during the quarter reduced by $1.3 million, or 43%, from the prior year period
• Reduced debt principal balance by $3.5 million, or 14%, and eliminated conversion feature of the convertible note
• Two-year performance data from the CASCADE clinical trial presented to the U.S. Food and Drug Administration (FDA), with an anticipated final response in the first quarter of 2016
• Received Brazilian clearance and shipped initial order of first generation silicon nitride interbody devices and instrumentation
• Designated world-renowned materials scientist Giuseppe Pezzotti, PhD to the Scientific Advisory Board
• Launched Valeo II™ lateral lumber interbody fusion device system and innovative articulating inserter for minimally invasive TLIF procedures
• Finalized definitive agreements to raise up to $15 million in equity financing, which will strengthen the Company’s balance sheet, reduce debt and be used for working capital

Amedica Corporation, a commercial-stage biomaterial company, develops, manufactures, and sells a range of medical devices based on its silicon nitride technology platform in the United States, Europe, and South America. It offers Valeo silicon nitride interbody spinal fusion devices for use in the cervical and thoracolumbar areas of the spine; and a line of non-silicon nitride spinal fusion products.

Rackspace Hosting, Inc. (NYSE:RAX)

On Thursday, Rackspace Hosting, Inc. (NYSE:RAX)’s shares declined -0.24% to $28.98.

RAX has the market capitalization of $3.90 billion. The stock has P/B ratio of 3.33 while EPS was $0.91. Institutional ownership of the company was 83.70% while 134.70 million shares were outstanding. Net profit margin of the Company was 6.30% while its gross profit margin was 67.30%. Share of the company moved above its SMA 50 with 5.09%. ROE ratio was 10.20% while ROI was 9.30%.

The mean estimate for the short term price target for Rackspace Hosting, Inc. (NYSE:RAX) stands at $39.47 according to 17 Analysts. The higher price target estimate for the stock has been calculated at $55.00 while the lower price target estimate is at $27.00.

Analysts mean recommendation for the stock is 2.20. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.

Rackspace Hosting, Inc. (Rackspace) operates in the managed cloud segment of the business information technology (IT) market. The Company offers a portfolio of integrated IT solutions for common business needs, including for e-commerce, Web content management, Website hosting, data services, office mail and collaboration,

Nantkwest Inc (NASDAQ:NK)

Nantkwest Inc (NASDAQ:NK)’s shares gained 5.85% to $17.20.

NK Its past 5-day performance at 44.54%. So far in 2015, the company has a year-to-date performance of -50.35%. The stock, as of last close, traded 70.30% up from its 52 week low and was -55.30% below its 52 week high. Its latest closing price was -6.68% below the SMA200 while the distance from SMA 50 and SMA 20 was 15.69% and 25.22% respectively.

The mean estimate for the short term price target for Nantkwest Inc (NASDAQ:NK) stands at $34.80 according to 5 Analysts. The higher price target estimate for the stock has been calculated at $38.00 while the lower price target estimate is at $30.00.

Analysts mean recommendation for the stock is 1.40. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.

NantKwest, Inc., formerly Conkwest, Inc., is a clinical-stage immunotherapy company. The Company is focused on harnessing the power of the innate immune system by using the natural killer (NK) cell to treat cancer, infectious diseases and inflammatory diseases.

Aduro BioTech Inc (NASDAQ:ADRO)

At the end of Thursday’s trade, Aduro BioTech Inc (NASDAQ:ADRO)‘s shares surged 0.71% to $28.46.

ADRO has market capitalization of $1.75 billion. Its current ratio was 20.20 while its shares were above its 50 days simple moving average with 15.69%. The company offered earning per share of $-0.86 while its 62.28 million shares were outstanding. YTD performance of the company was -32.24%. Stock volatility for the week was 12.51% while for the month it was shown at 11.25%.

The mean estimate for the short term price target for Aduro BioTech Inc (NASDAQ:ADRO) stands at $47.00 according to 5 Analysts. The higher price target estimate for the stock has been calculated at $74.00 while the lower price target estimate is at $30.00.

Analysts mean recommendation for the stock is 1.40. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.

Aduro BioTech Inc is a United States-based clinical-stage immunotherapy company. The Company has developed or acquired technology platforms designed to activate potent and lasting immune responses against cancer: live, attenuated Listeria, GVAX and cyclic dinucleotides (CDNs).

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.